Express Diagnostics International (EDI) recently notified RESPECT of a voluntary recall for its drug testing products that include BZO in the configuration. The reason for the recall is a risk of potential negative BZO results when evaluating urine containing Lorazepam, since it has no subsequent metabolite to which the test has demonstrated reactivity. EDI is offering replacement products to customers who have affected products that have remaining expiry dating. For more information regarding the EDI drug testing product recall, please review the FAQ.

Use the Lot Numbers of Affected Tests form to verify if you had or have any of the products affected by this recall.

The Customer Required Action document outlines what actions you should take if you had or have any products included in the affected lot numbers. If you currently have affected product, complete the Customer Verification Form and follow the included instructions for submission for replacement. If you have no remaining product, complete and return the Customer Verification Form.

If you have affected product to return, EDI will pay for the return shipping of the product. Please complete the Shipping Instruction form to request shipping labels.

If you have any additional questions about the EDI drug testing product recall, please contact RESPECT’s Commodities and Procurement Director Lindsey Boyington at (850) 942-3575 or by email.